Aron Goldhirsch

Summary

Country: Switzerland

Publications

  1. ncbi Adjuvant chemoendocrine therapy in postmenopausal breast cancer: cyclophosphamide, methotrexate, and fluorouracil dose and schedule may make a difference. International Breast Cancer Study Group
    A Goldhirsch
    Department of Medicine and Radiation Oncology, European Institute of Oncology, Milan, Italy
    J Clin Oncol 16:1358-62. 1998
  2. ncbi Systemic treatments for women with breast cancer: outcome with relation to screening for the disease
    A Goldhirsch
    Department of Medicine, European Institute of Oncology, Milan, Italy
    Ann Oncol 14:1212-4. 2003
  3. ncbi Meeting highlights: updated international expert consensus on the primary therapy of early breast cancer
    Aron Goldhirsch
    International Breast Cancer Study Group, Oncology Institute of Southern Switzerland, Lugano
    J Clin Oncol 21:3357-65. 2003
  4. ncbi New treatments for breast cancer: breakthroughs for patient care or just steps in the right direction?
    A Goldhirsch
    Department of Medical Oncology, European Institute of Oncology, Milan, Italy
    Ann Oncol 9:973-6. 1998
  5. ncbi Adding adjuvant CMF chemotherapy to either radiotherapy or tamoxifen: are all CMFs alike? The International Breast Cancer Study Group (IBCSG)
    A Goldhirsch
    Department of Medical Oncology, European Institute of Oncology, Milan, Italy
    Ann Oncol 9:489-93. 1998
  6. doi Role of endocrine responsiveness and HER2/neu overexpression in inflammatory breast cancer treated with multimodality preoperative therapy
    Claudia D'Alessandro
    Research Unit in Medical Senology, European Institute of Oncology, Milan, Italy
    Breast J 14:435-41. 2008
  7. doi Infusional fluorouracil, epirubicin, and cisplatin followed by weekly paclitaxel plus bevacizumab in locally advanced breast cancer with unfavorable prognostic features
    Alessandra Balduzzi
    Research Unit of Medical Senology, European Institute of Oncology, Milan, Italy
    Anticancer Drugs 20:197-203. 2009
  8. pmc A risk score based on histopathological features predicts higher risk of distant recurrence in premenopausal patients with lymph node-negative endocrine-responsive breast cancer
    Silvia Dellapasqua
    Medical Senology Research Unit and Division of Medical Oncology, Department of Medicine, European Institute of Oncology, Milan, Italy
    Breast 21:621-8. 2012
  9. ncbi A randomized phase II trial comparing preoperative plus perioperative chemotherapy with preoperative chemotherapy in patients with locally advanced breast cancer
    Andrea Rocca
    Unit of Research in Medical Senology, Department of Medicine, Division of Pathology, University of Milan School of Medicine, Italy
    Anticancer Drugs 17:1201-9. 2006
  10. ncbi Tailored preoperative treatment of locally advanced triple negative (hormone receptor negative and HER2 negative) breast cancer with epirubicin, cisplatin, and infusional fluorouracil followed by weekly paclitaxel
    Rosalba Torrisi
    Research Unit of Medical Senology, European Institute of Oncology, Via Ripamonti, 435 20141, Milan, Italy
    Cancer Chemother Pharmacol 62:667-72. 2008

Detail Information

Publications125 found, 100 shown here

  1. ncbi Adjuvant chemoendocrine therapy in postmenopausal breast cancer: cyclophosphamide, methotrexate, and fluorouracil dose and schedule may make a difference. International Breast Cancer Study Group
    A Goldhirsch
    Department of Medicine and Radiation Oncology, European Institute of Oncology, Milan, Italy
    J Clin Oncol 16:1358-62. 1998
    ..These drugs have since been extensively used with or without endocrine therapies and/or other cytotoxic agents. Although doses and schedules have varied widely, the combination of these three drugs is generically referred to as CMF...
  2. ncbi Systemic treatments for women with breast cancer: outcome with relation to screening for the disease
    A Goldhirsch
    Department of Medicine, European Institute of Oncology, Milan, Italy
    Ann Oncol 14:1212-4. 2003
    ..Research with tailored approaches on alternative imaging for early detection of breast cancer in high-risk women and on treatments offered according to proper criteria of responsiveness to therapies is warranted...
  3. ncbi Meeting highlights: updated international expert consensus on the primary therapy of early breast cancer
    Aron Goldhirsch
    International Breast Cancer Study Group, Oncology Institute of Southern Switzerland, Lugano
    J Clin Oncol 21:3357-65. 2003
    ....
  4. ncbi New treatments for breast cancer: breakthroughs for patient care or just steps in the right direction?
    A Goldhirsch
    Department of Medical Oncology, European Institute of Oncology, Milan, Italy
    Ann Oncol 9:973-6. 1998
    ..All three subjects represent important advances in cancer medicine...
  5. ncbi Adding adjuvant CMF chemotherapy to either radiotherapy or tamoxifen: are all CMFs alike? The International Breast Cancer Study Group (IBCSG)
    A Goldhirsch
    Department of Medical Oncology, European Institute of Oncology, Milan, Italy
    Ann Oncol 9:489-93. 1998
    ..Therefore, adherence to the 'classical' dose and schedule is recommended when CMF is used in adjuvant therapy...
  6. doi Role of endocrine responsiveness and HER2/neu overexpression in inflammatory breast cancer treated with multimodality preoperative therapy
    Claudia D'Alessandro
    Research Unit in Medical Senology, European Institute of Oncology, Milan, Italy
    Breast J 14:435-41. 2008
    ..91; 95% CI 1.69-20.7; p = 0.005), in particular if HER2/neu overexpression was detected (HR: 16.5; 95% CI 4.24-64.5; p < 0.0001). New multimodality and targeted strategies should be explored in endocrine nonresponsive breast cancer...
  7. doi Infusional fluorouracil, epirubicin, and cisplatin followed by weekly paclitaxel plus bevacizumab in locally advanced breast cancer with unfavorable prognostic features
    Alessandra Balduzzi
    Research Unit of Medical Senology, European Institute of Oncology, Milan, Italy
    Anticancer Drugs 20:197-203. 2009
    ..A non-negligible rate of progressive disease was observed, suggesting careful monitoring of the patients. Further studies evaluating the potential benefit of bevacizumab in neoadjuvant treatment need to be tested...
  8. pmc A risk score based on histopathological features predicts higher risk of distant recurrence in premenopausal patients with lymph node-negative endocrine-responsive breast cancer
    Silvia Dellapasqua
    Medical Senology Research Unit and Division of Medical Oncology, Department of Medicine, European Institute of Oncology, Milan, Italy
    Breast 21:621-8. 2012
    ..To develop a Risk Score (RS) to predict distant recurrence among premenopausal women with node-negative endocrine-responsive early breast cancer...
  9. ncbi A randomized phase II trial comparing preoperative plus perioperative chemotherapy with preoperative chemotherapy in patients with locally advanced breast cancer
    Andrea Rocca
    Unit of Research in Medical Senology, Department of Medicine, Division of Pathology, University of Milan School of Medicine, Italy
    Anticancer Drugs 17:1201-9. 2006
    ..Perioperative chemotherapy failed to show an increase in the pathological complete remission rate. A biological effect on Ki-67 expression was demonstrated...
  10. ncbi Tailored preoperative treatment of locally advanced triple negative (hormone receptor negative and HER2 negative) breast cancer with epirubicin, cisplatin, and infusional fluorouracil followed by weekly paclitaxel
    Rosalba Torrisi
    Research Unit of Medical Senology, European Institute of Oncology, Via Ripamonti, 435 20141, Milan, Italy
    Cancer Chemother Pharmacol 62:667-72. 2008
    ..No specific treatment guidelines are available for triple-negative breast cancers, defined by a lack of expression of estrogen (ER), progesterone (PgR), and HER2 receptors...
  11. pmc Classical cyclophosphamide, methotrexate, and fluorouracil chemotherapy is more effective in triple-negative, node-negative breast cancer: results from two randomized trials of adjuvant chemoendocrine therapy for node-negative breast cancer
    Marco Colleoni
    Research Unit in Medical Senology, Department of Medicine, European Institute of Oncology, Universita degli Studi di Milano, Milan, Italy
    J Clin Oncol 28:2966-73. 2010
    ....
  12. ncbi Effects of a treatment gap during adjuvant chemotherapy in node-positive breast cancer: results of International Breast Cancer Study Group (IBCSG) Trials 13-93 and 14-93
    Marco Colleoni
    Division of Medical Oncology, European Institute of Oncology, Milan, Italy
    Ann Oncol 18:1177-84. 2007
    ..The International Breast Cancer Study Group (IBCSG) conducted two complementary randomized trials to assess whether a treatment-free gap during adjuvant chemotherapy influenced outcome...
  13. pmc Is adjuvant chemotherapy of benefit for postmenopausal women who receive endocrine treatment for highly endocrine-responsive, node-positive breast cancer? International Breast Cancer Study Group Trials VII and 12-93
    Olivia Pagani
    Oncology Institute of Southern Switzerland, Ospedale Italiano, Viganello, Lugano, Switzerland
    Breast Cancer Res Treat 116:491-500. 2009
    ..03). Chemotherapy significantly improves disease-free survival for postmenopausal women with endocrine-responsive breast cancer, but the magnitude of the effect is substantially attenuated if ER levels are high...
  14. pmc Prognostic and predictive value of centrally reviewed Ki-67 labeling index in postmenopausal women with endocrine-responsive breast cancer: results from Breast International Group Trial 1-98 comparing adjuvant tamoxifen with letrozole
    Giuseppe Viale
    Division of Pathology and Laboratory Medicine, European Institute of Oncology, University of Milan, Milan, Italy
    J Clin Oncol 26:5569-75. 2008
    ..To evaluate the prognostic and predictive value of Ki-67 labeling index (LI) in a trial comparing letrozole (Let) with tamoxifen (Tam) as adjuvant therapy in postmenopausal women with early breast cancer...
  15. doi Neoadjuvant pegylated liposomal doxorubicin in combination with cisplatin and infusional fluoruracil (CCF) with and without endocrine therapy in locally advanced primary or recurrent breast cancer
    Rosalba Torrisi
    Research Unit of Medical Senology, European Institute of Oncology, Via Ripamonti 435, Milan, Italy
    Breast 20:34-8. 2011
    ..To explore the activity of pegylated liposomal doxorubicin (PLD) as neoadjuvant therapy of breast cancer...
  16. doi Topoisomerase IIalpha gene status and prediction of pathological complete remission after anthracycline-based neoadjuvant chemotherapy in endocrine non-responsive Her2/neu-positive breast cancer
    Laura Orlando
    Research Unit Medical Senology, European Institute of Oncology, Milan, Italy
    Breast 17:506-11. 2008
    ..We analyzed the role of Topo II gene status in the prediction of pathological complete remission (pCR) after primary anthracycline-based chemotherapy in non- endocrine responsive breast cancers overexpressing Her2/neu...
  17. pmc Trastuzumab in combination with metronomic cyclophosphamide and methotrexate in patients with HER-2 positive metastatic breast cancer
    Laura Orlando
    Unit of Research in Medical Senology, Department of Medicine, European Institute of Oncology, Via Ripamonti 435, 20141 Milan, Italy
    BMC Cancer 6:225. 2006
    ..We therefore tested the activity of the combination of Trastuzumab with metronomic, low dose chemotherapy with cyclophosphamide (CTX) and methotrexate (MTX) in metastatic breast cancer (MBC)...
  18. doi Invasive ductal carcinoma of the breast with the "triple-negative" phenotype: prognostic implications of EGFR immunoreactivity
    Giuseppe Viale
    Division of Pathology, European Institute of Oncology, Milan, Italy
    Breast Cancer Res Treat 116:317-28. 2009
    ..EGFR immunoreactivity significantly correlates with worse prognosis in patients with triple-negative IDC, supporting further studies on the correlation between the degree of EGFR expression and outcome of triple negative breast cancer...
  19. doi Chemoendocrine compared with endocrine adjuvant therapies for node-negative breast cancer: predictive value of centrally reviewed expression of estrogen and progesterone receptors--International Breast Cancer Study Group
    Giuseppe Viale
    Division of Pathology and Laboratory Medicine, European Institute of Oncology, University of Milan, Milan, Italy
    J Clin Oncol 26:1404-10. 2008
    ....
  20. doi Pathological complete response after preoperative systemic therapy and outcome: relevance of clinical and biologic baseline features
    Emilia Montagna
    Division of Medical Oncology, Department of Medicine, European Institute of Oncology, Via Ripamonti 435, 20141, Milan, Italy
    Breast Cancer Res Treat 124:689-99. 2010
    ..A substantial rate of relapse was observed for patients with large tumors and with clinical nodal involvement at baseline. Further improvement in adjuvant treatment might be warranted...
  21. doi Metronomic cyclophosphamide and capecitabine combined with bevacizumab in advanced breast cancer
    Silvia Dellapasqua
    Medical Senology Research Unit and Division of Medical Oncology, Department of Medicine, European Institute of Oncology, Milan, Italy
    J Clin Oncol 26:4899-905. 2008
    ..Metronomic chemotherapy has shown efficacy in patients with metastatic breast cancer. When used in association with targeted antiangiogenic drugs, it was more active than metronomic therapy alone in preclinical and clinical studies...
  22. doi Increased mean corpuscular volume of red blood cells predicts response to metronomic capecitabine and cyclophosphamide in combination with bevacizumab
    Silvia Dellapasqua
    Medical Senology Research Unit, Department of Medicine, European Institute of Oncology, Milan, Italy
    Breast 21:309-13. 2012
    ..There is an urgent need for the identification of commonly assessable predictive factors in the treatment of patients with metastatic breast cancer...
  23. ncbi Ipsilateral breast tumor reappearance in patients treated with conservative surgery after primary chemotherapy. The role of surgical margins on outcome
    Oreste Gentilini
    Division of Breast Surgery, European Institute of Oncology, Milan, Italy
    J Surg Oncol 94:375-9. 2006
    ..To evaluate the ipsilateral breast tumor reappearance (IBTR) rate after breast conservative surgery (BCS) following primary chemotherapy (PC) and to assess whether positive margins affects IBTR rate and overall survival (OS)...
  24. doi Preoperative concurrent chemo- and endocrine therapies for women with large operable breast cancer expressing steroid hormone receptors
    Rosalba Torrisi
    Research Unit in Medical Senology, European Institute of Oncology, Via Ripamonti 435, 20141 Milan, Italy
    Breast 17:654-60. 2008
    ..Endocrine therapy administered together with new intravenous, containing regimens should be explored in the preoperative treatment of endocrine responsive breast cancer...
  25. doi Predictive value of tumor Ki-67 expression in two randomized trials of adjuvant chemoendocrine therapy for node-negative breast cancer
    Giuseppe Viale
    Division of Pathology and Laboratory Medicine, European Institute of Oncology, University of Milan, Via Ripamoniti 435, Milan, Italy
    J Natl Cancer Inst 100:207-12. 2008
    ..Thus, Ki-67 labeling index was an independent prognostic factor but was not predictive of better response to adjuvant chemotherapy in these studies...
  26. doi Increasing steroid hormone receptors expression defines breast cancer subtypes non responsive to preoperative chemotherapy
    Marco Colleoni
    Department of Medicine, Research Unit in Medical Senology, European Institute of Oncology, Milan, Italy
    Breast Cancer Res Treat 116:359-69. 2009
    ..4, 95% CI 3.5-11.6, for DFS; HR 3.6 95% CI 2.4-5.6 for OS). Response and outcome after PCT are correlated with the degree of expression of steroid hormone receptors. Studies on tailored preoperative therapies are needed...
  27. doi Heterogeneity of triple-negative breast cancer: histologic subtyping to inform the outcome
    Emilia Montagna
    Research Unit in Medical Senology, Department of Medicine, European Institute of Oncology, Milan, Italy
    Clin Breast Cancer 13:31-9. 2013
    ..This study assesses outcome in terms of disease-free survival (DFS) and overall survival (OS) of special types of triple-negative breast cancer (TNBC)...
  28. doi Metronomic chemotherapy combined with bevacizumab and erlotinib in patients with metastatic HER2-negative breast cancer: clinical and biological activity
    Emilia Montagna
    Department of Medicine, European Institute of Oncology, Milan, Italy
    Clin Breast Cancer 12:207-14. 2012
    ..The analysis of the results suggests that the metronomic chemotherapy combined with bevacizumab and erlotinib is effective and well tolerated...
  29. ncbi Primary therapy with ECF in combination with a GnRH analog in premenopausal women with hormone receptor-positive T2-T4 breast cancer
    Rosalba Torrisi
    Research Unit of Medical Senology, Department of Medicine, European Institute of Oncology, Via Ripamonti 435, 20141 Milan, Italy
    Breast 16:73-80. 2007
    ..Further studies combining chemotherapy and endocrine agents are warranted in patients with hormone receptor-positive tumors...
  30. doi Pegylated liposomal doxorubicin in combination with low-dose metronomic cyclophosphamide as preoperative treatment for patients with locally advanced breast cancer
    Silvia Dellapasqua
    Medical Senology Research Unit, European Institute of Oncology, Via Ripamonti 435, 20141 Milan, Italy
    Breast 20:319-23. 2011
    ..To evaluate the role of pegylated liposomal doxorubicin with low-dose metronomic cyclophosphamide as primary systemic treatment in locally advanced breast cancer...
  31. doi Letrozole plus GnRH analogue as preoperative and adjuvant therapy in premenopausal women with ER positive locally advanced breast cancer
    Rosalba Torrisi
    Research Unit of Medical Senology at the Department of Medicine, European Institute of Oncology, Milano, Italy
    Breast Cancer Res Treat 126:431-41. 2011
    ....
  32. doi Clinical relevance of HER2 overexpression/amplification in patients with small tumor size and node-negative breast cancer
    Giuseppe Curigliano
    Department of Medicine, Division of Medical Oncology, Istituto Europeo di Oncologia, Milano, Italy
    J Clin Oncol 27:5693-9. 2009
    ..To assess the prognostic role of HER2 overexpression/amplification in patients with node-negative, pT1a-b breast cancers...
  33. doi Phase II trial of combination of pegylated liposomal doxorubicin, cisplatin, and infusional 5-fluorouracil (CCF) plus trastuzumab as preoperative treatment for locally advanced and inflammatory breast cancer
    Rosalba Torrisi
    Research Unit of Medical Senology, European Institute of Oncology, Milan, Italy
    Clin Breast Cancer 10:483-8. 2010
    ..Given its low cardiotoxicity, the combination of PLD and trastuzumab appears most attractive in the treatment of human epidermal factor receptor 2 (HER2)-positive breast cancer...
  34. doi Timing of adjuvant systemic therapy and radiotherapy after breast-conserving surgery and mastectomy
    Alessandra Balduzzi
    Research Unit of Medical Senology, European Institute of Oncology, Via Ripamonti 435, 20141 Milan, Italy
    Cancer Treat Rev 36:443-50. 2010
    ..This review focuses on the effects of timing of chemotherapy-radiotherapy and risks of relapse, in terms of locoregional and distant recurrence in patients with operable breast cancer...
  35. doi Preoperative therapy with trastuzumab and oral vinorelbine (+/- endocrine therapy) in patients with HER2-positive breast cancer
    Monica Iorfida
    Unit of Research in Medical Senology, European Institute of Oncology, Via Ripamonti 435, 20141, Milan, Italy
    Breast 19:128-32. 2010
    ..Combined trastuzumab and intravenous vinorelbine yielded high clinical activity as preoperative treatment in patients (pts) with HER 2/neu positive breast cancer...
  36. pmc Patterns of recurrence of early breast cancer according to estrogen receptor status: a therapeutic target for a quarter of a century
    Olivia Pagani
    Oncology Institute of Southern Switzerland, Ospedale Italiano, Viganello, Lugano, Switzerland
    Breast Cancer Res Treat 117:319-24. 2009
    ..Despite small numbers of patients, "old-fashioned" treatments, and competing causes of treatment failure, the value of ER status as a target for response to adjuvant treatment is evident through prolonged follow-up...
  37. ncbi Oral metronomic cyclophosphamide and methotrexate plus fulvestrant in advanced breast cancer patients: a mono-institutional case-cohort report
    Gaetano Aurilio
    European Institute of Oncology, Medical Oncology, Milan, Italy
    Breast J 18:470-4. 2012
    ..The prolonged clinical benefit, often desirable in such patients, supports this regimen as an additional and useful therapeutic tool...
  38. doi Prognostic value of circulating tumor cells according to immunohistochemically defined molecular subtypes in advanced breast cancer
    Elisabetta Munzone
    Division of Medical Oncology, Istituto Europeo di Oncologia, Milan, Italy
    Clin Breast Cancer 12:340-6. 2012
    ..Breast cancer is a heterogeneous disease. Circulating tumor cell (CTC) enumeration might be useful to identify different risk categories within each molecular subtype...
  39. doi Immunohistochemically defined subtypes and outcome in occult breast carcinoma with axillary presentation
    Emilia Montagna
    Division of Medical Oncology, Department of Medicine, Unit Research of Medical Senology, European Institute of Oncology, Via Ripamonti 435, 20141 Milan, Italy
    Breast Cancer Res Treat 129:867-75. 2011
    ..The outcome of OBC patients is comparable with that of matched patients with small sized breast cancer. High risk of relapse and death was observed in OBC patients with triple negative tumours and extensive nodal involvement...
  40. ncbi Chemotherapy is more effective in patients with breast cancer not expressing steroid hormone receptors: a study of preoperative treatment
    Marco Colleoni
    Department of Medicine, European Institute of Oncology, Milan, Italy
    Clin Cancer Res 10:6622-8. 2004
    ..The purpose of this research was to identify factors predicting response to preoperative chemotherapy...
  41. ncbi Modeling the relationship between circulating tumour cells number and prognosis of metastatic breast cancer
    Edoardo Botteri
    Division of Epidemiology and Biostatistics, European Institute of Oncology, Via Ripamonti 435, 20141 Milan, Italy
    Breast Cancer Res Treat 122:211-7. 2010
    ..If distinct prognostic groups are to be identified, women with no CTC could plausibly represent a distinct favorable one...
  42. ncbi Adjuvant therapy for very young women with breast cancer: response according to biologic and endocrine features
    Giuseppe Curigliano
    European Institute of Oncology, Milan, Italy
    Clin Breast Cancer 5:125-30. 2004
    ..The development of more effective therapies for very young women with breast cancer requires tailored treatment investigations and research focused on issues specific to these patients...
  43. ncbi Relation between chemotherapy dose, oestrogen receptor expression, and body-mass index
    Marco Colleoni
    European Institute of Oncology, Milan, Italy
    Lancet 366:1108-10. 2005
    ..44] for overall survival) [interaction p values=0.0001 for disease-free survival and 0.0019 for overall survival]. Our findings suggest that for women with ER-absent or ER-low tumours, reduction in chemotherapy dose should be avoided...
  44. doi Immunohistochemically defined subtypes and outcome of apocrine breast cancer
    Silvia Dellapasqua
    Research Unit in Medical Senology, Department of Medicine, European Institute of Oncology, Milan, Italy
    Clin Breast Cancer 13:95-102. 2013
    ..Conflicting data are available in the literature on the outcome of invasive apocrine carcinoma (IAC), possibly related to a heterogeneous classification of these tumors...
  45. ncbi Fulvestrant in heavily pre-treated patients with advanced breast cancer: results from a single compassionate use programme centre
    Chiara Catania
    Unit for Medical Care, Division of Medical Oncology, European Institute of Oncology, 20141, Milan, Italy
    Breast Cancer Res Treat 106:97-103. 2007
    ..The drug was administered to heavily pre-treated patients with advanced breast cancer (ABC). Patients received Fulvestrant after disease progression (PD) on a previous endocrine treatment or as maintenance treatment after chemotherapy...
  46. ncbi Pathologic complete remission rate after cisplatin-based primary chemotherapy in breast cancer: correlation with p63 expression
    Andrea Rocca
    Research Unit in Medical Senology, European Institute of Oncology, Milan, Italy
    Cancer Chemother Pharmacol 61:965-71. 2008
    ..The aim of the present study was to ascertain the predictive value of p63 immunoreactivity in patients treated preoperatively with regimens including cisplatin and/or anthracyclines...
  47. ncbi Tamoxifen after adjuvant chemotherapy for premenopausal women with lymph node-positive breast cancer: International Breast Cancer Study Group Trial 13-93
    Marco Colleoni
    Division of Medical Oncology, European Institute of Oncology, Via Ripamonti 435, 20141, Milan, Italy
    J Clin Oncol 24:1332-41. 2006
    ..The value of adjuvant tamoxifen after chemotherapy for premenopausal women with breast cancer has not been adequately assessed...
  48. doi Weekly epirubicin in the treatment of gestational breast cancer (GBC)
    Fedro A Peccatori
    Department of Medicine, European Institute of Oncology, Via Ripamonti 435, 20141, Milan, Italy
    Breast Cancer Res Treat 115:591-4. 2009
    ..GBC is a rare disease and chemotherapy in this setting lacks a standardized approach...
  49. doi A nomogram based on the expression of Ki-67, steroid hormone receptors status and number of chemotherapy courses to predict pathological complete remission after preoperative chemotherapy for breast cancer
    Marco Colleoni
    Department of Medicine, Research Unit in Medical Senology, European Institute of Oncology, Milan, Italy
    Eur J Cancer 46:2216-24. 2010
    ..Tools able to predict pathological complete response (pCR) to preoperative chemotherapy might improve treatment outcome...
  50. ncbi Perioperative serum VEGF and extracellular domains of EGFR and HER2 in early breast cancer
    Andrea Rocca
    Research Unit in Medical Senology, Division of Medical Oncology, European Institute of Oncology, Via Ripamonti 435, 20141, Milan, Italy
    Anticancer Res 29:5111-9. 2009
    ..The prognostic role of serum levels of molecular biomarkers during the perioperative period in patients with early breast cancer is not clear...
  51. doi Invasive lobular breast cancer: subtypes and outcome
    Monica Iorfida
    Research Unit in Medical Senology, Department of Medicine, European Institute of Oncology, Milan, Italy
    Breast Cancer Res Treat 133:713-23. 2012
    ..The outcome of ILC significantly correlated with histological and immunohistochemically defined molecular subtypes. New tailored strategies should be explored in these subgroups of patients with poor outcome...
  52. doi Breast cancer and pregnancy: how safe is trastuzumab?
    Hatem A Azim
    Department of Medicine, European Institute of Oncology, Via Ripamonti 435, Milan, Italy
    Nat Rev Clin Oncol 6:367-70. 2009
    ..During the tenth month of trastuzumab therapy, the patient reported a missed period and had a positive pregnancy test...
  53. ncbi Prolonged clinical benefit with metronomic chemotherapy in patients with metastatic breast cancer
    Laura Orlando
    Unit of Research in Medical Senology, European Institute of Oncology, Via Ripamonti 435, 20141 Milan, Italy
    Anticancer Drugs 17:961-7. 2006
    ..Metronomic chemotherapy can induce prolonged clinical benefit in metastatic breast cancer, supporting its role as an additional therapeutic tool in the treatment of patients with metastatic breast carcinoma...
  54. doi Lack of prognostic significance of "classic" lobular breast carcinoma: a matched, single institution series
    Giuseppe Viale
    European Institute of Oncology, University of Milan, Italy
    Breast Cancer Res Treat 117:211-4. 2009
    ..Classical lobular histology is not an independent factor in the prognosis of early breast cancer...
  55. ncbi Breast phyllodes tumor: a review of literature and a single center retrospective series analysis
    Gianluca Spitaleri
    Department of Medicine, European Institute of Oncology, Milan, Italy Electronic address
    Crit Rev Oncol Hematol 88:427-36. 2013
    ..We carried out an overview of the literature to investigate the clinical outcome of patients with phyllodes tumor. A retrospective analysis of mono-institutional series has been included as well...
  56. ncbi Discordant hormone receptor and human epidermal growth factor receptor 2 status in bone metastases compared to primary breast cancer
    Gaetano Aurilio
    Medical Oncology, European Institute of Oncology, Milan, Italy
    Acta Oncol 52:1649-56. 2013
    ....
  57. ncbi A meta-analysis of oestrogen receptor, progesterone receptor and human epidermal growth factor receptor 2 discordance between primary breast cancer and metastases
    Gaetano Aurilio
    European Institute of Oncology, Medical Oncology, Via Ripamonti 435, Milan, Italy Electronic address
    Eur J Cancer 50:277-89. 2014
    ..However, results from different studies are heterogeneous and often conflicting. To highlight this issue, a meta-analysis of published data was performed...
  58. pmc Axillary dissection versus no axillary dissection in patients with sentinel-node micrometastases (IBCSG 23-01): a phase 3 randomised controlled trial
    Viviana Galimberti
    Molecular Senology Unit, Senology Division, European Institute of Oncology, Milan, Italy
    Lancet Oncol 14:297-305. 2013
    ..We designed IBCSG trial 23-01 to determine whether no axillary dissection was non-inferior to axillary dissection in patients with one or more micrometastatic (≤2 mm) sentinel nodes and tumour of maximum 5 cm...
  59. ncbi Low-dose aspirin for the prevention of venous thromboembolism in breast cancer patients treated with infusional chemotherapy after insertion of central vein catheter
    Giuseppe Curigliano
    Division of Medical Oncology, Department of Medicine, European Institute of Oncology, Via Ripamonti 435, 20141 Milan, Italy
    Support Care Cancer 15:1213-7. 2007
    ..The aim of this study was to evaluate the efficacy and safety of low-dose aspirin for the prevention of VTE...
  60. ncbi Clinicopathologic characteristics of 143 patients with synchronous bilateral invasive breast carcinomas treated in a single institution
    Mattia Intra
    Division of Breast Surgery, European Institute of Oncology, Milan, Italy
    Cancer 101:905-12. 2004
    ..Synchronous bilateral invasive breast carcinoma (SBIBC) ranged in incidence from 0.3% to as high as 12%...
  61. ncbi HER2 status in early breast cancer: relevance of cell staining patterns, gene amplification and polysomy 17
    Rosalba Torrisi
    Department of Medicine, European Institute of Oncology, Via Ripamonti 435, 20141, Milan, Italy
    Eur J Cancer 43:2339-44. 2007
    ..Our results suggest that FISH testing should be considered for tumours with 50% positive stained cells and that polysomy 17 without amplification is not associated with poor prognostic features...
  62. pmc Circulating endothelial-cell kinetics and viability predict survival in breast cancer patients receiving metronomic chemotherapy
    Patrizia Mancuso
    Division of Hematology Oncology, Department of Medicine, European Institute of Oncology, Milan, Italy
    Blood 108:452-9. 2006
    ..005). Preclinical models indicated that the source of apoptotic CECs was most likely the tumor vasculature. CEC kinetics and viability are very promising as predictors of clinical response in patients undergoing metronomic chemotherapy...
  63. ncbi Are there benefits in routine clinical practice of continuing trastuzumab after progression for metastatic breast cancer patients?
    Angela Esposito
    Department of Medicine, European Institute of Oncology, Milan, Italy
    Anticancer Drugs 23:1089-98. 2012
    ..Our retrospective data suggest that treatment with trastuzumab beyond progression is a viable option for patients with advanced HER2-positive breast cancer, whose disease has progressed on previous trastuzumab-based regimens...
  64. doi Biopsy of liver metastasis for women with breast cancer: impact on survival
    Edoardo Botteri
    Division of Epidemiology and Biostatistics, European Institute of Oncology, Milan, Italy
    Breast 21:284-8. 2012
    ..Biopsy of metastatic site of disease can influence treatment decisions, but its impact on survival remains uncertain...
  65. doi The biological features and prognosis of breast cancer diagnosed during pregnancy: a case-control study
    Hatem A Azim
    Department of Medicine, European Institute of Oncology, Via Ripamonti 435, Milan, Italy
    Acta Oncol 51:653-61. 2012
    ..Hence, we designed a case-control study to examine tumor features and outcome in a series of BCP patients diagnosed and treated in a single institution...
  66. ncbi Capecitabine/vinorelbine: an effective and well-tolerated regimen for women with pretreated advanced-stage breast cancer
    Franco Nole
    Department of Medicine, European Institute of Oncology, Milan, Italy
    Clin Breast Cancer 6:518-24. 2006
    ....
  67. doi Immunizing against breast cancer: a new swing for an old sword
    Giuseppe Curigliano
    European Institute of Oncology, Department of Medicine, Division of Medical Oncology, Via Ripamonti 435, Milan, Italy
    Breast 18:S51-4. 2009
    ....
  68. ncbi Size of breast cancer metastases in axillary lymph nodes: clinical relevance of minimal lymph node involvement
    Marco Colleoni
    Division of Medical Oncology, Department of Medicine, Istituto Europeo di Oncologia, Via Ripamonti 435, 20141, Milan, Italy
    J Clin Oncol 23:1379-89. 2005
    ....
  69. doi Changes of HER2 status in circulating tumor cells compared with the primary tumor during treatment for advanced breast cancer
    Elisabetta Munzone
    Division of Medical Oncology, European Institute of Oncology, Milan, Italy
    Clin Breast Cancer 10:392-7. 2010
    ..HER2/neu status of tumor cells at metastatic sites in patients with advanced disease may differ from that of the primary tumor. Assessing the presence of target antigens on circulating tumor cells (CTCs) might affect treatment choice...
  70. doi Sentinel lymph node biopsy in pregnant patients with breast cancer
    Oreste Gentilini
    Division of Senology, European Institute of Oncology, Milan, Italy
    Eur J Nucl Med Mol Imaging 37:78-83. 2010
    ..Sentinel lymph node biopsy (SLNB) is currently not recommended in pregnant patients with breast cancer due to radiation concerns...
  71. pmc Reverting estrogen-receptor-negative phenotype in HER-2-overexpressing advanced breast cancer patients exposed to trastuzumab plus chemotherapy
    Elisabetta Munzone
    Department of Medicine, Division of Medical Oncology, European Institute of Oncology, Via Ripamonti 435, 20141 Milan, Italy
    Breast Cancer Res 8:R4. 2006
    ..These sequences of events indicate that a phenotype based on ER expression may not be a permanent feature of breast cancer...
  72. doi Participation in clinical trials as viewed by the patient: understanding cultural and emotional aspects which influence choice
    Chiara Catania
    Division of Medical Oncology, European Institute of Oncology, Milan, Italy
    Oncology 74:177-87. 2008
    ..Patients invited to take part in a clinical trial may evoke an archetype on which they may base their decision of adherence to participation, instead of on the study itself...
  73. ncbi Adjuvant endocrine therapy for premenopausal women with early breast cancer
    Silvia Dellapasqua
    Division of Medical Oncology, Department of Medicine, European Institute of Oncology, Via Ripamonti 435, 20141 Milan, Italy
    J Clin Oncol 23:1736-50. 2005
  74. ncbi Rethinking TNM: breast cancer TNM classification for treatment decision-making and research
    Umberto Veronesi
    European Institute of Oncology, Via Ripamonti 435, 20141 Milan, Italy
    Breast 15:3-8. 2006
    ..The significant changes we propose are:..
  75. pmc Analyses adjusting for selective crossover show improved overall survival with adjuvant letrozole compared with tamoxifen in the BIG 1-98 study
    Marco Colleoni
    European Institute of Oncology, Milan, Italy
    J Clin Oncol 29:1117-24. 2011
    ..We investigated whether letrozole monotherapy prolonged overall survival (OS) compared with tamoxifen monotherapy...
  76. doi Lessons on responsiveness to adjuvant systemic therapies learned from the neoadjuvant setting
    Marco Colleoni
    Research Unit in Medical Senology, Department of Medicine, European Institute of Oncology, Via Ripamonti 435, Milan, Italy
    Breast 18:S137-40. 2009
    ..We review recent developments in the knowledge of established predictive factors in the neo-adjuvant setting...
  77. ncbi Prognostic and predictive value of centrally reviewed expression of estrogen and progesterone receptors in a randomized trial comparing letrozole and tamoxifen adjuvant therapy for postmenopausal early breast cancer: BIG 1-98
    Giuseppe Viale
    Division of Pathology and Laboratory Medicine, European Institute of Oncology, University of Milan, Milan, Italy
    J Clin Oncol 25:3846-52. 2007
    ..To evaluate locally versus centrally assessed estrogen (ER) and progesterone (PgR) receptor status and the impact of PgR on letrozole adjuvant therapy compared with tamoxifen in postmenopausal women with early breast cancer...
  78. pmc The 6th Milan Breast Cancer Conference, Milan, Italy, 16-18 June 2004
    Roberto Gennari
    European Institute of Oncology, Milano, Italy
    Breast Cancer Res 7:E1. 2005
  79. ncbi Breast cancer
    Umberto Veronesi
    European Institute of Oncology, Milan, Italy
    Lancet 365:1727-41. 2005
    ..Assessment of potential molecular targets is now important in primary diagnosis. Tyrosine-kinase inhibitors and other drugs with anti-angiogenesis properties are currently undergoing preclinical investigations...
  80. ncbi Perception that oral anticancer treatments are less efficacious: development of a questionnaire to assess the possible prejudices of patients with cancer
    Chiara Catania
    Division of Medical Oncology, Day Hospital Unit and Unit of Psycho oncology, Department of Medicine, European Institute of Oncology, Milan, Italy
    Breast Cancer Res Treat 92:265-72. 2005
    ..The questionnaire was shown to be robust, reliable and reproducible instrument in assessing patients' prejudices towards oral anticancer treatments...
  81. ncbi Site of primary tumor has a prognostic role in operable breast cancer: the international breast cancer study group experience
    Marco Colleoni
    Division of Medical Oncology, European Institute of Oncology, Via Ripamonti 435, 20141 Milan, Italy
    J Clin Oncol 23:1390-400. 2005
    ..For medial tumors, axillary lymph node staging may not accurately reflect the metastatic potential of the disease...
  82. ncbi New criteria for selecting elderly patients for breast cancer adjuvant treatment studies
    Silvia Dellapasqua
    European Institute of Oncology, Via Ripamonti 435, 20141 Milan, Italy
    Oncologist 12:952-9. 2007
    ..Disclosure of potential conflicts of interest is found at the end of this article...
  83. ncbi Vaccine immunotherapy in breast cancer treatment: promising, but still early
    Giuseppe Curigliano
    European Institute of Oncology, Department of Medicine, Division of Medical Oncology, Via Ripamonti 435, 20141 Milan, Italy
    Expert Rev Anticancer Ther 7:1225-41. 2007
    ..Another focus of the review is to provide the reader with future challenges in the field, taking into account both the immunological and clinical aspects to better target the goal...
  84. ncbi Results of chest wall resection for recurrent or locally advanced breast malignancies
    Giulia Veronesi
    Division of Thoracic Surgery, European Institute of Oncology, Via Ripamonti 435, 20141 Milan, Italy
    Breast 16:297-302. 2007
    ....
  85. ncbi Erlotinib-induced breast cancer regression
    Chiara Catania
    Medical Care Unit, Department of Medicine, European Institute of Oncology, Milan, Italy
    Ann Pharmacother 40:2043-7. 2006
    ..To report a case of erlotinib-induced breast cancer regression...
  86. ncbi Mediastinal lymphoadenopathy in a patient with breast cancer
    Guiseppe Curigliano
    Department of Medicine, European Institute of Oncology, Milan, Italy
    Lancet Oncol 3:174. 2002
  87. ncbi Breast carcinoma in elderly women: features of disease presentation, choice of local and systemic treatments compared with younger postmenopasual patients
    Roberto Gennari
    Department of Surgery, European Institute of Oncology, Milan, Italy
    Cancer 101:1302-10. 2004
    ..The aim of the study was to evaluate the relation between biologic features at first diagnosis of breast carcinoma and treatment choice for postmenopausal women > or = 50 years to optimize treatment in the elderly...
  88. ncbi Innovation in care and research: meeting highlights from the seventh Milan Breast Cancer Conference (Milan, 15-17 June, 2005)
    Saverio Cinieri
    European Institute of Oncology, Via Ripamonti 435, 20141 Milan, Italy
    Breast 15:232-45. 2006
    ..This meeting report summarizes the highlights of the 12 sessions...
  89. doi Conservative surgery in patients with multifocal/multicentric breast cancer
    Oreste Gentilini
    Division of Breast Surgery, European Institute of Oncology, Milan, Italy
    Breast Cancer Res Treat 113:577-83. 2009
    ..We retrospectively evaluate outcome of patients with MF/MC cancers who had breast conservation with specific attention on local control and predictive factors of recurrence...
  90. ncbi Immunology and breast cancer: therapeutic cancer vaccines
    Giuseppe Curigliano
    Department of Medicine, Division of Medical Oncology, European Institute of Oncology, Via Ripamonti 435, 20141 Milano, Italy
    Breast 16:S20-6. 2007
    ....
  91. ncbi A randomized trial of low-dose tamoxifen on breast cancer proliferation and blood estrogenic biomarkers
    Andrea Decensi
    Division of Chemoprevention, European Institute of Oncology, and University of Milan School of Medicine, Milan, Italy
    J Natl Cancer Inst 95:779-90. 2003
    ....
  92. ncbi Intrathecal chemotherapy in carcinomatous meningitis from breast cancer
    Laura Orlando
    Division of Medical Oncology, European Institute of Oncology, Via Ripamonti 435, 20141 Milan, Italy
    Anticancer Res 22:3057-9. 2002
    ..We therefore evaluated the efficacy of an ITC regimen for patients presenting with carcinomatous meningitis from breast cancer...
  93. ncbi Adjuvant systemic therapies for patients with breast cancer: endocrine responsiveness and effects of chemotherapy
    Marco Colleoni
    Division of Medical Oncology, European Institute of Oncology, Milan, Italy
    Curr Probl Cancer 27:13-6. 2003
  94. ncbi Toremifene and tamoxifen are equally effective for early-stage breast cancer: first results of International Breast Cancer Study Group Trials 12-93 and 14-93
    Olivia Pagani
    Instituto Oncologico Svizzera Italiana IOSI, Ospedale Beata Vergine, Mendrisio, Switzerland
    Ann Oncol 15:1749-59. 2004
    ..This is the first report of the endocrine comparison after a median follow-up of 5.5 years...
  95. ncbi Adjuvant chemotherapy followed by goserelin versus either modality alone for premenopausal lymph node-negative breast cancer: a randomized trial
    Monica Castiglione-Gertsch
    International Breast Cancer Study Group Coordinating Center and Inselspital, Bern, Switzerland
    J Natl Cancer Inst 95:1833-46. 2003
    ....
  96. ncbi Adjuvant chemotherapy in breast cancer: back to the future
    Marco Colleoni
    Onkologie 26:111-2. 2003
  97. ncbi The role of the number of uninvolved lymph nodes in predicting locoregional recurrence in breast cancer
    Per Karlsson
    Department of Oncology, University of Goteborg, Sahlgrenska University Hospital, Goteborg, Sweden
    J Clin Oncol 25:2019-26. 2007
    ..To identify groups of early breast cancer patients with substantial risk (10-year risk > 20%) for locoregional failure (LRF) who might benefit from postmastectomy radiotherapy (RT)...
  98. ncbi Adjuvant chemotherapy (ECF regimen) for patients with gastric adenocarcinoma
    Piercarlo Saletti
    Istituto Oncologico della Svizzera Italiana IOSI, Bellinzona, Switzerland
    Hepatogastroenterology 54:969-72. 2007
    ..ECF is an active regimen in advanced gastric adenocarcinoma (GAC). We used ECF as an adjuvant therapy in a cohort of patients with GAC who underwent curative surgery and describe their results in terms of feasibility and outcome...
  99. ncbi Adjuvant endocrine therapy compared with no systemic therapy for elderly women with early breast cancer: 21-year results of International Breast Cancer Study Group Trial IV
    Diana Crivellari
    Centro di Riferimento Oncologico, Via Pedemontana Occidentale 12, I 33081 Aviano, Italy
    J Clin Oncol 21:4517-23. 2003
    ..The role of adjuvant therapy for this population is still a matter of debate. We reviewed the long-term outcome of a mature trial comparing endocrine treatment versus no adjuvant therapy in older women with node-positive breast cancer...
  100. ncbi Breast cancer in the elderly
    Diana Crivellari
    Division of Medical Oncology C, Centro di Riferimento Oncologico National Cancer Institute, Aviano, PN Italy
    J Clin Oncol 25:1882-90. 2007
    ....
  101. ncbi Prognostic value of extracapsular tumor spread for locoregional control in premenopausal patients with node-positive breast cancer treated with classical cyclophosphamide, methotrexate, and fluorouracil: long-term observations from International Breast Ca
    Günther Gruber
    Department of Radiation Oncology, and the Institute of Medical Oncology, Inselspital, Switzerland
    J Clin Oncol 23:7089-97. 2005
    ..We sought to determine retrospectively whether extracapsular spread (ECS) might identify a subgroup that could benefit from radiotherapy after mastectomy, especially patients with 1 to 3 positive lymph nodes (LN1-3+)...